CERDELGA DIN 02463261
Health Canada record
| Active ingredient(s) | ELIGLUSTAT (ELIGLUSTAT TARTRATE) 84 MG |
|---|---|
| Dosage form | Capsule |
| Route | Oral |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | A16AX10 ELIGLUSTAT |
| Original market date | 26-Jul-2017 |
| Current status date | 14-Oct-2024 |
| Source | Health Canada DPD |
Establishment licence of the holder
sanofi-aventis Canada Inc. — licence 101470, currently licensed, last inspection rating C (2026-02-17).
No Canadian shortage report is currently matched to this DIN.
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 33071 | 2024-04-17 | New Drug Submission (NDS) | Administrative: Change in Product Ownership |
| 19194 | 2017-04-21 | New Drug Submission (NDS) |